II. Indications
-
Tension Headache (Occipital Headache)
- Trigger Point Injection at trapzius insertion
-
Myofascial Pain Syndrome
- Symptomatic active Trigger Point AND
- Twitch response to pressure with referred pain
III. Contraindications
- Known Bleeding Disorder
- Anticoagulation (includes Aspirin in last 3 days)
- Local or systemic infection
- Acute Trauma at Muscle site
- Anesthetic allergy
- Suspicion for non-Myofascial Pain (e.g. malignancy)
- Unsafe injection site (e.g. underlying neurovascular structures)
- Example: Intercostal space (risk of Pneumothorax)
IV. Mechanism
- Mechanical disruption of Trigger Point
- Dry needle "poking" of Trigger Points is also effective
- However, may result in more post-injection soreness
- Injections are specifically for Trigger Points
- Trigger Points on compression result in referred pain
- Injections are not simply tender
V. Preparation
- Medications
- Bupivicaine (Sensorcaine) 0.25%: 5 cc total
- May be used alone (effective) or with Corticosteroid
- Triamcinolone (Kenalog) 40 mg/ml: 1 cc
- Some studies demonstrate no additional benefit with Corticosteroid versus Anesthetic alone
- Mechanism of Trigger Point Injection effect is likely more than antiinflammatory activity
- Myofascial Pain does not appear to be inflammatory
- In addition to lack of benefit, Corticosteroids have risks (Hyperglycemia, infection, skin atrophy)
- Normal Saline (or dy needling)
- Non-inferior to Lidocaine 1% with Triamcinolone injection
- Roldan (2020) Am J Emerg Med 38(2): 311-6 [PubMed]
- Bupivicaine (Sensorcaine) 0.25%: 5 cc total
- Needle selection
- Select needle of adequate length
- Prevents burying needle to hub (risk or breakage)
- Select needle of adequate gauge
- Allows for necessary mechanical disruption
- Less likely to be deflected from taut Muscle
- Needle examples
- Shallow sites
- Optimal: 25-27 gauge 1.25 to 1.5 inch needle
- Alternative: Tuberculin syringe (5/8 inch)
- Deeper sites or obese patient
- Spinal needle (21 gauge 2.5 inch needle)
- Shallow sites
- Select needle of adequate length
VI. Technique
- Position patient comfortably
- Patient identifies one to four Trigger Points (painful regions)
- See Trigger Point Location
- Mark the most Tender Points on palpation (1-2 cm regions of spasm) with a surgical pen
- Most common Trigger Points for injection are trapezius, levator Scapulae and neck Muscles
- Consider performing under Ultrasound guidance when in the region of important structures (e.g. neurovascular, lung)
- Anticipate initial increased pain on injection
- Local twitch and referred pain confirms placement
- Injecting near Trigger Point may cause irritation
- Start with most tender spot in Trigger Point (identified via palpation)
- Localize most tender spot within taut Muscle-fibers
- Fix tender spot between fingers (1-2 cm in size)
- Prevents from rolling away from needle
- Controls subcutaneous bleeding
- Cleanse overlying skin
- Inject Trigger Point
- Select needle as above
- Warn patient of possible pain on injection (associated with pH of medication, tissue expansion)
- Slowly injecting may reduce pain
- Direct needle at 30 degree angle off skin
- Insert needle into skin 1-2 cm from Trigger Point
- Advance needle into Trigger Point
- Use 1-2 ml Anesthetic total at each Trigger Point
- Use a fanning technique of injection (0.3 to 0.5 ml at a time)
- Repeat until local twitch or tautness resolves
- Cycles of redirecting needle and reinjecting
- Withdraw needle to subcutaneous tissue
- Redirect needle into adjacent tender areas
- Hold direct pressure at injection site for 1-2 minutes
- Prevents Hematoma formation
- Helps distribute Anesthetic
- Repeat procedure for other Tender Points
- Patient gently stretches injected areas
- Full active range of motion in all directions
- Repeat range of motion three times after injection
VII. Management: Post-Procedure Instructions (Reduce postinjection flare)
- Patient avoids over-using injected area for 3-4 days
- Maintain active range of motion of injected Muscle
- Patient applies ice to injected areas for a few hours
- Anticipate post-injection soreness for 3-4 days
VIII. Complications
- Local Skin Infection at injection site
- Local Hematoma at injection site
- Pneumothorax
- Medication Hypersensitivity
- Peripheral Nerve Injury
IX. Course
- Expect 2-4 months of benefit after injection
X. Precautions
- Avoid repeat injection if unsuccessful on 2-3 attempts
- Re-evaluate for possible repeat injection after 4 days
XI. References
- Ruoff in Pfenninger (1994) Procedures, Mosby, p. 164-7
- Sola in Roberts (1998) Procedures, Saunders, p. 890-901
- Strayer in Herbert (2016) EM:Rap 16(11): 1-2
- Warrington (2020) Crit Dec Emerg Med 34(9): 14
- Alvarez (2002) Am Fam Physician 65(4):653-60 [PubMed]
- Fomby (1997) Phys Sportsmed 25(2):67-75 [PubMed]
- Shipton (2023) Am Fam Physician 107(2): 159-64 [PubMed]